BioSenic SA is a biotechnology company with extensive scientific and clinical experience in the field of orthopedics and regenerative therapies, specializing in the clinical development of therapies for bone and cartilage repair. BioSenic SA still holds stakes in its clinical assets ALLOB and JTA, but is now focusing on joint development with 4Moving Biotech of a GLP-1-based disease-modifying therapy for veterinary use, particularly for recovery after ligament surgery in dogs. BioSenic SA is also focusing on other potential new partnerships.

Employees

Sector

Pharmaceuticals

More about the company

25-10-27	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-10-02	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI

Market Cap	1.5M 1.74M 1.74M 1.38M 1.3M 2.44M 165M 2.46M 16.34M 6.38M 80.63M 6.54M 6.4M 279M	P/E Ratio 2023	-0.29x	P/E Ratio 2024	-0.28x
Enterprise Value	28.84M 33.46M 33.46M 26.54M 24.9M 46.77M 3.16B 47.24M 314M 123M 1.55B 126M 123M 5.36B	EV / Sales 2023	113x	EV / Sales 2024	286x
Free-Float	85.86%	Yield 2023 *	-	Yield 2024	-

25-10-27	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-10-02	BioSenic S.A. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-09-28	Bone Therapeutics SA Reports Earnings Results for the Full Year Ended December 31, 2024	CI
24-10-28	BioSenic S.A. Announces Executive Changes	CI
24-09-30	BioSenic S.A. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-09-29	Bone Therapeutics SA Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-09-17	BioSenic Deputy CEO Steps Down	MT
24-09-17	Véronique Pomi-Schneiter Step Down as BioSenic's Deputy CEO	CI
24-08-14	BioSenic Unit Secures European Patent for Multiple Sclerosis Treatment	MT
24-08-14	Medsenic, Subsidiary of Biosenic Receives the Intention to Grant Key European Patent from European Patent Office	CI
24-08-13	BioSenic Grants of A Key Patent by the Japan Patent Office to Expand Protection of the Arsenic Trioxide Platform	CI
24-07-18	Biosenic Releases New In-Depth Analysis of Its Positive Phase 2 Clinical Data for Optimal Administration Scheme for Its Next Late-Stage Trial of Arsenic Trioxide Targeting Cgvhd	CI
24-07-05	BioSenic Seeks US Patent Extension for Sepsis Drug	MT

12-14	BioSenic : Report from Auditor on ESEF format 2024 Annual Report	PU
25-09-25	BioSenic : appoints CarKath SRL, represented by Mr Eric Halioua, as chairman of the board of directors	PU
25-08-29	BioSenic : provides an update on the preparation of the annual accounts and annual report for the financial year ending on 31 December 2024	PU
25-08-04	BioSenic : announces the homologation by the Enterprise Court of BioSenic's amicable agreements with five main creditors to restructure over €22 million of debt and appointment of two new independent directors	PU
25-07-01	BioSenic : announces partnership with 4Moving Biotech and secures its financing.	PU

05-07	BioSenic : Procuration pour l'actionnaire
05-07	BioSenic : Rapport annuel 2025
05-07	BioSenic : Communiqué de Presse - Convocation à l'Assemblée Générale Ordinaire
04-28	BioSenic : BIOS PR 2026 avril Denominator FR20260428
04-12	BioSenic : annonce l'émission de droits de souscription au bénéfice de membres du conseil d'administration

Bone Therapeutics SA Stock Euronext Bruxelles

Stocks

BOTHE

BE0974280126

Pharmaceuticals

Valuation: Bone Therapeutics SA

Latest news : Bone Therapeutics SA

Analysts' recommendations: Bone Therapeutics SA

Press Releases: Bone Therapeutics SA

News in other languages: Bone Therapeutics SA

Managers and Directors: Bone Therapeutics SA

Other Pharmaceuticals

Financials

Company Profile

Director	Title	Age	Since
Jean-Luc Vandebroek BRD	Director/Board Member	55	2021-12-31
Eric Halioua CHM	Chairman	-	2025-08-31
Virginie Miath BRD	Director/Board Member	-	2026-01-28

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.32%	-1.72%	+37.83%	+148.79%	1,010B
JOHNSON & JOHNSON	-2.16%	+1.51%	+50.01%	+43.93%	580B
ABBVIE INC.	-2.70%	-0.66%	+15.97%	+63.07%	402B
ROCHE HOLDING AG	-1.18%	+1.05%	+20.91%	+18.37%	330B
NOVARTIS AG	-1.52%	+2.45%	+23.73%	+33.03%	281B
ASTRAZENECA PLC	-1.95%	-4.32%	+20.15%	+12.96%	280B
NOVO NORDISK A/S	-0.57%	+5.00%	-44.67%	-48.28%	197B
AMGEN INC.	-1.31%	+1.39%	+18.74%	+53.45%	192B
GILEAD SCIENCES, INC.	-0.38%	-2.97%	+13.02%	+57.34%	156B
Average	-1.24%	+0.02%	+17.30%	+42.52%	380.97B
Weighted average by Cap.	-1.03%	-0.16%	+26.16%	+67.03%

	2023	2024
Net sales	336K 390K 390K 309K 290K 545K 36.84M 550K 3.66M 1.43M 18.04M 1.46M 1.43M 62.43M	102K 118K 118K 93.87K 88.07K 165K 11.18M 167K 1.11M 434K 5.48M 444K 435K 18.95M
Net income	-28.78M -33.39M -33.39M -26.49M -24.85M -46.67M -3.16B -47.14M -313M -122M -1.55B -125M -123M -5.35B	-4.77M -5.53M -5.53M -4.39M -4.12M -7.73M -523M -7.81M -51.88M -20.26M -256M -20.76M -20.32M -886M
Net Debt	28.04M 32.53M 32.53M 25.81M 24.21M 45.48M 3.07B 45.93M 305M 119M 1.51B 122M 120M 5.21B	27.34M 31.72M 31.72M 25.16M 23.6M 44.33M 3B 44.78M 297M 116M 1.47B 119M 116M 5.08B

End-of-day quote Euronext Bruxelles Other stock markets
-	-